“The scientific and business teams at AltheaDx have been a joy to work with. Their collaborative approach to making our key therapeutic projects their number one priority makes them truly a part of our team. I highly recommend them.” —  Executive Director, Research and Development. [More]

AltheaDx announces appointment of new CEO and President and adds Dr. Ann Kessler to the Board of Directors

San Diego, CA, April 28, 2010 – AltheaDx, Inc., a privately held molecular diagnostics company and a leader in the development of companion diagnostics for biopharmaceutical partners, today announced that Wendy Benson has been appointed CEO and President, replacing interim co-CEOs, Drs. François Ferré and Magda Marquet.  Additionally, the company announced the appointment of Dr. Ann Kessler and Wendy Benson to the AltheaDx Board of Directors. [More]

AltheaDx and The Nicholas Conor Institute for Pediatric Cancer Research Announce Molecular Diagnostics Collaboration to Improve the Diagnosis and Treatment of Childhood Cancer

SAN DIEGO, April 18, 2010--AltheaDx, Inc., a leader in the development of companion diagnostics, and The Nicholas Conor Institute for Pediatric Cancer Research, announced today that they have entered into collaboration to: develop a broad panel of diagnostic, prognostic, and treatment prediction information for pediatric cancer, provide actionable information to attending physicians that will best guide treatment for pediatric cancer, and achieve a significant milestone towards The Nicholas Conor Institute’s mission of improving diagnosis and treatment of pediatric cancer. [More]